RIVFLOZA's Patent Review Period Locked In by FDA
Published Date: 6/16/2025
Notice
Summary
The FDA has set the official review period for RIVFLOZA, a new drug, so its patent can be extended. This helps the drug maker get extra time to protect their invention before generic versions can appear. If you’re involved in drug patents or healthcare, this timing update matters for when RIVFLOZA stays exclusive and when competition can start.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Patent extension gives maker extra exclusivity
The FDA has set the regulatory review period for RIVFLOZA so the drug’s patent can be extended. If you own or manage the patent for RIVFLOZA, this lets you get extra time to protect the invention before competitors can enter the market.
Generic competition may be delayed
The FDA’s determination supports a patent extension for RIVFLOZA, which means generic versions may not be able to appear as soon. If you are a patient, health care provider, or payer, the timing for when competition starts for RIVFLOZA could be later because of this extension.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in